We pretended that we do not know the identity of compound and the goal was to use this treatment sample as a query to our BRCA MoNet to predict its MoA. Note that E2 is a compound tested in the cMap data and also included in our BRCA MoNet. Therefore, an accurate prediction algorithm would be expected www.selleckchem.com/products/mek162.html to rank E2 asso ciated MoA on the top of the predicted MoA list for similar treatment effect and possibly rank MoAs associated with estrogen receptor antagonist at the top of the reverse pre diction list. The top similar predictions are shown in Table 2. All the drugs are ranked based on their MoA gene signatures reversely related with E2. In the prediction result, the MoA that contains E2 was ranked the 2nd among all the 109 MoAs and E2 is ranked the 4th among the total 504 MCF7 effective drugs selected for BRCA MoNet.

This result indicates that our BRCA MoNet can achieve very high precision. We investigated more closely the E2 associated BRCA MoA64 and found that among 17 drugs, 11 are known to be related to estrogen. Specifically, three of them were different forms of estrogen and six others are different forms of progestogen, a precursor of estrogen. Epiandrosterone can induce androgenic activ ity, which can also lead to a precursor of estrogen, and Epi tiostanol is a form of anti estrogen. Among the remaining six drugs, Naringenin is a weak estrogenic bioflavonoid that exhibits anti estrogenic activity . Aminophylline is known to interact with estrogen . kaempferol is a diet ary flavonoid that functions as a selective estrogen receptor modulator .

Oxybenzone is a compound widely used in the sunscreen and a few studies suggested that oxybenzone mimics the effects of the estrogen and may cause higher risk to breast cancer. Lorglumide has been shown to induce opposite effect of estrogen in . only nefopam has no evidence that sug gests any interaction with estrogen and breast cancer. This significant over representation of the estrogen related com pounds Dacomitinib in the E2 associate MoA provides strong evidence to suggest that the constructed MoAs in our BRCA MoNet do contain drugs of similar effect. Next, we predicted the MoAs with the reverse treatment effect. The result is equally promising. In the highest ranked MoA, two of three drugs are selective estrogen receptor modulators, which have anti estrogenic actions, and the other one is an anti breast cancer drug.

The second ranked MoA, BRCA MoA86, contains one drug bacampicilin. Bacampicilin is a penicillin antibiotic and study showed that it interacts with estrogen to reduce the effect of estrogen. The third ranked MoA, BRCA MoA52, contains two drugs cyproterone and nabumetone. Cyproerone is a steroidal anti androgen with additional pro gestogen together and anti gonadotropic properties. It can sup press the activity of the androgen hormones and subse quently reduce the productivity of estrogen.